• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.

作者信息

Hughes David M, Henshaw Lynnette, Blevins Frances, Edwards Camille, Lerner Adam, Sloan John Mark, Sanchorawala Vaishali

机构信息

Department of Pharmacy, Boston Medical Center, Boston, MA; School of Medicine, Boston University, Boston, MA; Department of Hematology and Oncology, Boston Medical Center, Boston, MA.

Department of Pharmacy, Boston Medical Center, Boston, MA; Department of Hematology and Oncology, Boston Medical Center, Boston, MA.

出版信息

Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):566-568. doi: 10.1016/j.clml.2022.03.003. Epub 2022 Mar 9.

DOI:10.1016/j.clml.2022.03.003
PMID:35367193
Abstract
摘要

相似文献

1
Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.对于接受皮下注射达雷妥尤单抗治疗的多发性骨髓瘤和轻链淀粉样变性患者，30分钟的标准监测时间和强度较低的预处理是安全的。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):566-568. doi: 10.1016/j.clml.2022.03.003. Epub 2022 Mar 9.
2
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于新诊断的与多发性骨髓瘤相关的系统性轻链淀粉样变患者
Br J Haematol. 2022 Aug;198(3):e38-e41. doi: 10.1111/bjh.18234. Epub 2022 May 7.
3
Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience.达雷妥尤单抗治疗复发/难治性轻链型淀粉样变性患者的真实世界使用模式及疗效：单中心经验
Leuk Lymphoma. 2022 May;63(5):1246-1250. doi: 10.1080/10428194.2021.2018585. Epub 2022 Jan 2.
4
Daratumumab proves safe and highly effective in AL amyloidosis.达雷妥尤单抗在AL淀粉样变性中被证明是安全且高效的。
Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25.
5
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.首个周期达雷妥尤单抗对多发性骨髓瘤和AL淀粉样变性治疗服务影响的真实世界数据。
Br J Haematol. 2018 Sep;182(6):936-939. doi: 10.1111/bjh.14897. Epub 2017 Aug 18.
6
Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC).达雷妥尤单抗治疗复发/难治性 AL 型淀粉样变性：来自卡尔加里淀粉样变性项目（APC）的经验
Leuk Lymphoma. 2024 Mar;65(3):403-406. doi: 10.1080/10428194.2023.2290468. Epub 2023 Dec 6.
7
Future Developments in Light Chain Amyloidosis Management.轻链淀粉样变性管理的未来发展。
Am J Med. 2022 Apr;135 Suppl 1:S53-S57. doi: 10.1016/j.amjmed.2022.01.007. Epub 2022 Jan 23.
8
Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.达雷妥尤单抗治疗高浆细胞负荷的复发/难治性 AL 淀粉样变性。
Hematol Oncol. 2019 Dec;37(5):595-600. doi: 10.1002/hon.2677. Epub 2019 Nov 6.
9
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.达雷妥尤单抗治疗复发性 AL 淀粉样变性症——当累积真实世界数据先于临床试验时：一项多中心研究和系统文献复习。
Eur J Haematol. 2021 Feb;106(2):184-195. doi: 10.1111/ejh.13535. Epub 2020 Nov 9.
10
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.一项在既往治疗的系统性轻链淀粉样变性患者中应用达雷妥尤单抗的前瞻性 2 期临床试验。
Blood. 2020 Apr 30;135(18):1531-1540. doi: 10.1182/blood.2019004369.

引用本文的文献

1
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.多发性骨髓瘤下一代新型疗法的毒性管理策略
Ther Adv Hematol. 2022 Jul 15;13:20406207221100659. doi: 10.1177/20406207221100659. eCollection 2022.